Evergen is a Contract Development and Manufacturing Organization (CDMO) founded in 1998, specializing in innovation and tissue engineering for regenerative medicine. The company focuses on technical domains including tissue engineering, regenerative medicine, and biomaterials development.
Evergen manufactures a comprehensive portfolio of allograft and xenograft biomaterials at scale. Its operational scale is evidenced by delivering over 20 million implants, securing more than 200 market authorizations, and obtaining over 50 FDA 510(k) clearances. The company's industry verticals span regenerative medicine, plastic and reconstructive surgery, sports medicine and orthopedics, neuro/spine, and cardiac sectors.
Headquartered in Alachua, Florida, Evergen maintains a geographic presence across the United States, Europe, and New Zealand. It operates with a patient-first CDMO partnership model, serving as a trusted partner to OEMs with clinical expertise and an agile partnership approach.
